Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia

被引:21
作者
Heilmann, CAU
Attmann, T
Thiem, A
Haffner, E
Beyersdorf, F
Lutter, G
机构
[1] Univ Schleswig Holstein, Sch Med, Dept Cardiovasc Surg, D-24105 Kiel, Germany
[2] Univ Hosp Freiburg, Dept Cardiovasc Surg, Freiburg, Germany
关键词
growth factors; gene therapy; coronary disease; molecular biology;
D O I
10.1016/S1010-7940(03)00455-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Growth factor gene therapy represents one current approach in the therapy of myocardial ischemia. We assessed the in vitro and in vivo expression of naked plasmid DNA aiming at preservation of function in a chronically ischemic myocardial model. Methods: In vitro: Primary cardiac fibroblasts were transfected with plasmids encoding enhanced green fluorescent protein, human VEGF(121), human FGF-2, or porcine MCP-1. Protein synthesis was assessed microscopically, by ELISA, Western blotting, or intracellular immunofluorescence. In vivo: A LAD stenosis was created in healthy pigs. One week later, segmental myocardial shortening (SMS) and systemic hemodynamics (left ventricular stroke work index, LVSWI time derivative of left ventricular pressure, dp/dt(max)) were assessed at baseline. Afterwards. the ischemic area received either intramyocardial injections of naked cytokine plasmid DNA or vector only, or was left untreated. One myocardial sample taken 1 h after plasmid injection was subjected to RT-PCR and PCR. After 3 months, cardiac function was re-examined. Results: In vitro: Transfection of cardiac fibroblasts resulted in high gene expression for several days. In vivo: Plasmid-specific DNA and mRNA were found 1 h after plasmid injection (n = 1). After 3 months, VEGF, FGF-2, and vector rendered better results of regional contractility at rest and of LVSWI. However, only VEGF and FGF-2 were effective with regard to regional contractility under dobutamine stress and to left ventricular contractility. Conclusion: In conclusion, intramyocardial injection of naked plasmid DNA encoding VEGF121 or FGF-2 improved myocardial function in chronic ischemia in more aspects than vector only and was superior to untreated ischemia or MCP-1. This strategy can be considered a successful tool for growth factor stimulated preservation of function in chronic myocardial ischemia. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:785 / 793
页数:9
相关论文
共 23 条
  • [1] VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
    Asahara, T
    Takahashi, T
    Masuda, H
    Kalka, C
    Chen, DH
    Iwaguro, H
    Inai, Y
    Silver, M
    Isner, JM
    [J]. EMBO JOURNAL, 1999, 18 (14) : 3964 - 3972
  • [2] GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function
    Buschmann, IR
    Hoefer, IE
    van Royen, N
    Katzer, E
    Braun-Dulleaus, R
    Heil, M
    Kostin, S
    Bode, C
    Schaper, W
    [J]. ATHEROSCLEROSIS, 2001, 159 (02) : 343 - 356
  • [3] Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
    Cao, RH
    Bråkenhielm, E
    Pawliuk, R
    Wariaro, D
    Post, MJ
    Wahlberg, E
    Leboulch, P
    Cao, YH
    [J]. NATURE MEDICINE, 2003, 9 (05) : 604 - 613
  • [4] Mechanisms of angiogenesis and arteriogenesis
    Carmeliet, P
    [J]. NATURE MEDICINE, 2000, 6 (04) : 389 - 395
  • [5] Angiogenesis in transmyocardial revascularization: Comparison of laser versus mechanical punctures
    Chu, VF
    Giaid, A
    Kuang, JQ
    McGinn, AN
    Li, CM
    Pelletier, MP
    Chiu, RCJ
    [J]. ANNALS OF THORACIC SURGERY, 1999, 68 (02) : 301 - 308
  • [6] Biological activities of fibroblast growth factor-2 in the adult myocardium
    Detillieux, KA
    Sheikh, F
    Kardami, E
    Cattini, PA
    [J]. CARDIOVASCULAR RESEARCH, 2003, 57 (01) : 8 - 19
  • [7] Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia
    Fuchs, S
    Baffour, R
    Zhou, YF
    Shou, M
    Pierre, A
    Tio, FO
    Weissman, NJ
    Leon, MB
    Epstein, SE
    Kornowski, R
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (06) : 1726 - 1732
  • [8] Gene therapy in transplantation: pathological consequences of unavoidable plasmid contamination with lipopolysaccharide
    Gordillo, GM
    Xia, DY
    Mullins, AN
    Bergese, SD
    Orosz, CG
    [J]. TRANSPLANT IMMUNOLOGY, 1999, 7 (02) : 83 - 94
  • [9] Comparison of protein with DNA therapy for chronic myocardial ischemia using fibroblast growth factor-2
    Heilmann, C
    von Samson, P
    Schlegel, K
    Attmann, T
    von Specht, BU
    Beyersdorf, F
    Lutter, G
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2002, 22 (06) : 957 - 964
  • [10] Assessment of risks associated with cardiovascular gene therapy in human subjects
    Isner, JM
    Vale, PR
    Symes, JF
    Losordo, DW
    [J]. CIRCULATION RESEARCH, 2001, 89 (05) : 389 - 400